Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma

Clin Nucl Med. 2016 Jan;41(1):83-5. doi: 10.1097/RLU.0000000000000995.


Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell / diagnostic imaging*
  • Carcinoma, Renal Cell / pathology
  • Fluorodeoxyglucose F18
  • Humans
  • Lysine / analogs & derivatives
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Neoplasm Metastasis
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Tomography, X-Ray Computed
  • Urea / analogs & derivatives


  • 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Urea
  • Lysine